Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA4 | P22748 | 2/20 | 0.36 |
| ▸ | CA6 | P23280 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514350 | 0.80 | L3MBTL1 (0.43) | L3MBTL1SMN1; SMN2PTPN1MAPTNPSR1 | |
| SCHEMBL459755 | 0.78 | POLB (0.38) | L3MBTL1SMN1; SMN2POLBMAPTALDH1A1 | |
| SCHEMBL8951911 | 0.76 | SMN1; SMN2 (0.41) | L3MBTL1SMN1; SMN2PTPN1MAPTNPSR1 | |
| SCHEMBL6517406 | 0.75 | L3MBTL1 (0.55) | L3MBTL1MAPTPTGS2ALDH1A1GAA | |
| SCHEMBL18480665 | 0.74 | CA1 (0.50) | SMN1; SMN2PTPN1PTGS2CA1CA2 | |
| SCHEMBL8752544 | 0.68 | KMT2A (0.51) | L3MBTL1POLBNPSR1ALDH1A1CA1 | |
| SCHEMBL13978736 | 0.68 | ACHE (0.46) | L3MBTL1SMN1; SMN2POLBMAPTNPSR1 | |
| SCHEMBL18354589 | 0.68 | ACHE (0.46) | L3MBTL1POLBMAPTNPSR1RAB9A | |
| SCHEMBL457840 | 0.68 | CYP3A4 (0.42) | L3MBTL1SMN1; SMN2POLBALDH1A1GAA | |
| SCHEMBL10723623 | 0.68 | CA12 (0.46) | SMN1; SMN2POLBMAPTNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | WELLSTAT BIOCATALYSIS, LLC | 2005-06-09 | — | — | US | disclosed |
| US-6702705-B1 | Prodrugs activated by targeted catalytic proteins | IGEN INTERNATIONAL, INC. | 2004-03-09 | — | — | US | disclosed |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | IGEN, INC. | 2003-05-22 | — | — | US | disclosed |
| US-6258360-B1 | BENZOATE CONJUGATES; ANTITUMOR AGENTS | IGEN INTERNATIONAL, INC. | 2001-07-10 | — | — | US | disclosed |
| CN-1044911-C | Process for preparing prodrug | IGEN INC (US) | 1999-09-01 | — | — | CN | disclosed |
| CN-1217335-A | Method for preparing precursor medicine | IGEN INC (US) | 1999-05-26 | — | — | CN | disclosed |
| CN-1070409-A | Prodrugs activated by targetted catalytic proteins | IGEN INC (US) | 1993-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123533-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | L3MBTL1 3131/4885SMN1; SMN2 4221/4885PTPN1 561/4885 |
| US-20030096765-A1 | Prodrugs activated by targeted catalytic proteins | DNPH1, DNPEP, PNP | L3MBTL1 3131/4885SMN1; SMN2 4221/4885PTPN1 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.